- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02306720
Registry of Patients With Hypophosphatasia
July 11, 2023 updated by: Alexion
An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)
In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.
Study Overview
Status
Enrolling by invitation
Conditions
Detailed Description
The HPP Registry is an observational, prospective, long-term registry designed to collect data on HPP epidemiology, disease history, clinical course, symptoms and burden of disease from patients of all ages who have a diagnosis of HPP.
Evaluation of safety and effectiveness data in patients with HPP who have/are receiving treatment with Asfotase alfa
Study Type
Observational
Enrollment (Estimated)
900
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Herston, Australia
-
South Brisbane, Australia
-
-
New South Wales
-
Westmead, New South Wales, Australia
-
-
Victoria
-
Clayton, Victoria, Australia
-
Parkville, Victoria, Australia
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
-
-
-
Lyon, France
-
-
Haute Garonne
-
Toulouse, Haute Garonne, France
-
-
Paris
-
Paris cedex 14, Paris, France
-
-
Île-de-France
-
Le Kremlin-Bicêtre, Île-de-France, France
-
-
-
-
-
Berlin, Germany
-
Giessen, Germany
-
Hamburg, Germany
-
Homburg, Germany
-
Koeln, Germany
-
Mainz, Germany
-
Muenchen, Germany
-
Müllheim, Germany
-
Rostock, Germany
-
-
Bayern
-
Bad Reichenhall, Bayern, Germany
-
Würzburg, Bayern, Germany
-
-
Nordrhein Westfalen
-
Bochum, Nordrhein Westfalen, Germany
-
Düsseldorf, Nordrhein Westfalen, Germany
-
-
Sachsen
-
Dresden, Sachsen, Germany
-
-
-
-
-
Firenze, Italy
-
Pisa, Italy
-
Rome, Italy
-
San Giovanni Rotondo, Italy
-
Verona, Italy
-
-
-
-
-
Warsaw, Poland
-
-
-
-
-
Moscow, Russian Federation
-
Saint Petersburg, Russian Federation
-
-
-
-
-
Riyadh, Saudi Arabia
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
-
-
-
-
Belfast, United Kingdom
-
Birmingham, United Kingdom
-
Dundee, United Kingdom
-
Leicester, United Kingdom
-
London, United Kingdom
-
Newcastle upon Tyne, United Kingdom
-
Newport, United Kingdom
-
Norwich, United Kingdom
-
Oxford, United Kingdom
-
Sheffield, United Kingdom
-
Stanmore, United Kingdom
-
-
Avon
-
Bristol, Avon, United Kingdom
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
-
-
Colorado
-
Centennial, Colorado, United States, 80112
-
Golden, Colorado, United States, 80401
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
-
-
Florida
-
Tampa, Florida, United States, 33606
-
-
Georgia
-
Decatur, Georgia, United States, 30033
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
-
Saint Louis, Missouri, United States, 63110
-
-
New York
-
Mineola, New York, United States, 11501
-
Rochester, New York, United States, 14642
-
Syracuse, New York, United States, 13214
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
-
Columbus, Ohio, United States, 43205
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with Hypophosphatasia (HPP)
Description
Inclusion Criteria:
- Male and female participants, of any age, with a confirmed diagnosis of HPP.
- Participant must have documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
- Participant or legal representative is able to read and/or understand the informed consent and study questionnaires in the local language.
- Signed informed consent and medical records release by the patient or legal representative. Patient or patient's parent/legal representative must be willing and able to give written informed consent, and the patient must be willing to give written informed assent, if appropriate and required by local regulations.
Exclusion Criteria:
- Currently participating in an Alexion-sponsored clinical trial. Enrollment in the Registry will not exclude a patient from enrolling in a future clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Natural History Information
Time Frame: 1 Year
|
To collect information on the natural history of HPP from patients of all ages, including pediatric patients and adults with HPP, regardless of age at onset.
|
1 Year
|
Burden of Disease/Patient-reported Outcomes
Time Frame: 1 year
|
Age-appropriate PRO data will be collected using instruments to asses below: Pain, Motor Capacity, Functional Status/Disability, including Activities of Daily Living (ADL), Quality of Life (QoL)
|
1 year
|
Characterize the epidemiology of the HPP population.
Time Frame: 1 year
|
To characterize the epidemiology of the HPP population.
Inclusion of all classifications of HPP is planned: pediatric-onset (perinatal-, infantile-, and juvenile-onset), adult-onset, benign perinatal, and odontohypophosphatasia.
|
1 year
|
Long-Term Safety and Effectiveness of Asfotase Alfa
Time Frame: 1 year
|
To collect and evaluate long-term safety and effectiveness data in HPP patients who have/are receiving treatment with asfotase alfa.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Seefried L, Dahir K, Petryk A, Hogler W, Linglart A, Martos-Moreno GA, Ozono K, Fang S, Rockman-Greenberg C, Kishnani PS. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. J Bone Miner Res. 2020 Nov;35(11):2171-2178. doi: 10.1002/jbmr.4130. Epub 2020 Aug 10.
- Hogler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K, Petryk A, Rockman-Greenberg C, Seefried L, Kishnani PS. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019 Feb 14;20(1):80. doi: 10.1186/s12891-019-2420-8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 31, 2014
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
August 28, 2030
Study Registration Dates
First Submitted
November 26, 2014
First Submitted That Met QC Criteria
December 1, 2014
First Posted (Estimated)
December 3, 2014
Study Record Updates
Last Update Posted (Actual)
July 12, 2023
Last Update Submitted That Met QC Criteria
July 11, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALX-HPP-501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypophosphatasia (HPP)
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada, United Arab Emirates, United Kingdom
-
Hvidovre University HospitalOdense University HospitalActive, not recruitingHypophosphatasia (HPP)Denmark
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Turkey, Australia, Germany, United Kingdom, Argentina, France, Canada, India
-
Alexion Pharmaceuticals, Inc.Not yet recruiting
-
AlexionRecruiting